Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Papadopoulos

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Personalized Medicine|May 16, 2018
Mapping genes for oligodendrogliomaChetan Bettegowda, Nicholas Papadopoulos, Nishant Agrawal
Melanoma Research|June 5, 2003
Phase II evaluation of temozolomide in metastatic choroidal melanomaAgop Y Bedikian, Nicholas Papadopoulos, Carl Plager, et al.
Melanoma Research|April 20, 2004
Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanomaAgop Y Bedikian, Carl Plager, Nicholas Papadopoulos, et al.
Bioanalysis|March 21, 2019
Anti-VEGF drug interference with VEGF quantitation in the R&D systems human quantikine VEGF ELISA kitGiane Sumner, Camille Georgaros, Ashique Rafique, et al.
Cancer|May 27, 2003
Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomasShreyaskumar R Patel, Jennifer Beach, Nicholas Papadopoulos, et al.
Cancer|October 21, 2010
Prognostic factors for survival in melanoma patients with brain metastasesMichael A Davies, Ping Liu, Susan McIntyre, et al.
Journal of Immunotoxicology|June 24, 2008
Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survivalAgop Y Bedikian, Marcella M Johnson, Carla L Warneke, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 26, 2012
Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapyRahat Noor, Agop Y Bedikian, Sandy Mahoney, et al.
EXS|December 25, 2004
The anti-inflammatory actions of angiopoietin-1Gavin Thurston, John S Rudge, Ella Ioffe, et al.
Development (Cambridge, England)|June 17, 2005
Angiopoietin 1 causes vessel enlargement, without angiogenic sprouting, during a critical developmental periodGavin Thurston, Quan Wang, Fabienne Baffert, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Personalized Medicine|May 16, 2018
Mapping genes for oligodendrogliomaChetan Bettegowda, Nicholas Papadopoulos, Nishant Agrawal
Melanoma Research|June 5, 2003
Phase II evaluation of temozolomide in metastatic choroidal melanomaAgop Y Bedikian, Nicholas Papadopoulos, Carl Plager, et al.
Melanoma Research|April 20, 2004
Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanomaAgop Y Bedikian, Carl Plager, Nicholas Papadopoulos, et al.
Bioanalysis|March 21, 2019
Anti-VEGF drug interference with VEGF quantitation in the R&D systems human quantikine VEGF ELISA kitGiane Sumner, Camille Georgaros, Ashique Rafique, et al.
Cancer|May 27, 2003
Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomasShreyaskumar R Patel, Jennifer Beach, Nicholas Papadopoulos, et al.
Cancer|October 21, 2010
Prognostic factors for survival in melanoma patients with brain metastasesMichael A Davies, Ping Liu, Susan McIntyre, et al.
Journal of Immunotoxicology|June 24, 2008
Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survivalAgop Y Bedikian, Marcella M Johnson, Carla L Warneke, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 26, 2012
Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapyRahat Noor, Agop Y Bedikian, Sandy Mahoney, et al.
EXS|December 25, 2004
The anti-inflammatory actions of angiopoietin-1Gavin Thurston, John S Rudge, Ella Ioffe, et al.
Development (Cambridge, England)|June 17, 2005
Angiopoietin 1 causes vessel enlargement, without angiogenic sprouting, during a critical developmental periodGavin Thurston, Quan Wang, Fabienne Baffert, et al.
Pageof 4